BACKGROUND: The literature contains conflicting findings on the influence of gender and HIV transmission group on the initial prescription of highly active antiretroviral therapy (HAART) and its biological and clinical efficacy. METHODS: We conducted a cohort study involving 62 French hospitals. We used Cox proportional hazards models to examine whether gender and HIV transmission group influenced the timing of elective HAART initiation, and the clinical and biological response to treatment. RESULTS: We studied 5735 patients enrolled between January 1997 and December 2001 who did not start HAART or develop a stage C HIV-related event during the first 3 months after inclusion. In multivariate analysis, no gender differences were found in the interval between enrollment in the database and HAART initiation, but this interval was shorter in homosexual patients than in other transmission groups; CD4 cell counts at treatment initiation were also higher in the homosexual group. The immunovirological response to treatment did not differ according to gender, but was better in homosexual patients than in patients in other categories. Injecting drug users had the weakest immunovirological responses. Clinical outcome was not related to gender or to HIV transmission group. CONCLUSIONS: The interval between diagnosis of HIV-1 infection and elective HAART initiation was not influenced by gender. However, homosexual patients had higher CD4 cell counts than other patients at treatment initiation, and also had better immunovirological responses.
BACKGROUND: The literature contains conflicting findings on the influence of gender and HIV transmission group on the initial prescription of highly active antiretroviral therapy (HAART) and its biological and clinical efficacy. METHODS: We conducted a cohort study involving 62 French hospitals. We used Cox proportional hazards models to examine whether gender and HIV transmission group influenced the timing of elective HAART initiation, and the clinical and biological response to treatment. RESULTS: We studied 5735 patients enrolled between January 1997 and December 2001 who did not start HAART or develop a stage C HIV-related event during the first 3 months after inclusion. In multivariate analysis, no gender differences were found in the interval between enrollment in the database and HAART initiation, but this interval was shorter in homosexual patients than in other transmission groups; CD4 cell counts at treatment initiation were also higher in the homosexual group. The immunovirological response to treatment did not differ according to gender, but was better in homosexual patients than in patients in other categories. Injecting drug users had the weakest immunovirological responses. Clinical outcome was not related to gender or to HIV transmission group. CONCLUSIONS: The interval between diagnosis of HIV-1 infection and elective HAART initiation was not influenced by gender. However, homosexual patients had higher CD4 cell counts than other patients at treatment initiation, and also had better immunovirological responses.
Authors: A Plettenberg; N H Brockmeyer; B Haastert; C Michalik; S Dupke; K Schewe; M Rausch; M Hower; A Ulmer; E Wolf; T Lorenzen; G Arendt; K Jansen Journal: Infection Date: 2011-01-11 Impact factor: 3.553
Authors: Muktar H Aliyu; Meridith Blevins; Karen M Megazzini; Deidra D Parrish; Carolyn M Audet; Naomi Chan; Chisom Odoh; Usman I Gebi; Mukhtar Y Muhammad; Bryan E Shepherd; C William Wester; Sten H Vermund Journal: Int Health Date: 2015-05-25 Impact factor: 2.473
Authors: S Esser; A Haberl; F Mulcahy; J Gölz; A Lazzarin; E Teofilo; J Vera; A Körber; S Staszewski Journal: Eur J Med Res Date: 2011-10-10 Impact factor: 2.175
Authors: Laure-Amélie de Monteynard; Rosemary Dray-Spira; Pierre de Truchis; Sophie Grabar; Odile Launay; Jean-Luc Meynard; Marie-Aude Khuong-Josses; Jacques Gilquin; David Rey; Anne Simon; Juliette Pavie; Aba Mahamat; Sophie Matheron; Dominique Costagliola; Sophie Abgrall Journal: PLoS One Date: 2015-03-03 Impact factor: 3.240